272
Participants
Start Date
September 15, 2022
Primary Completion Date
July 31, 2027
Study Completion Date
December 31, 2028
JANX007
JANX007 is dosed via IV in a 21- or 28-day cycle.
Darolutamide
Darolutamide is dosed via oral tablets
RECRUITING
Chris O'Brien Lifehouse (COBLH), Camperdown
RECRUITING
Southern Oncology Clinical Research Unit (SoCRU), Bedford Park
RECRUITING
Linear Clinical Research Ltd., Nedlands
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Weill Cornell Medicine, New York
RECRUITING
Montefiore Medical Center, The Bronx
RECRUITING
Northwell Health R.J. Zuckerberg Cancer Hospital, Lake Success
RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
RECRUITING
Penn State Milton S. Hershey Medical Center, Hershey
RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
University of Alabama at Birmingham Hospital, Birmingham
RECRUITING
Sarah Cannon Research, Nashville
RECRUITING
University of Minnesota Medical Center, Minneapolis
RECRUITING
University of Chicago Medical Center, Chicago
RECRUITING
Washington University School of Medicine, St Louis
RECRUITING
Mary Crowley Cancer Research, Dallas
RECRUITING
University of Texas Southwestern Medical Center, Dallas
RECRUITING
Houston Methodist Hospital, Houston
RECRUITING
UCLA Department of Medicine, Los Angeles
RECRUITING
Hoag Memorial Hospital Presbyterian, Newport Beach
RECRUITING
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
RECRUITING
University of California Davis Comprehensive Cancer Center, Sacramento
RECRUITING
Oregon Health and Science University, Portland
RECRUITING
Yale New Haven Hospital, New Haven
ACTIVE_NOT_RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Rhode Island Hospital, Providence
Lead Sponsor
Janux Therapeutics
INDUSTRY